Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of molecular remission after stopping tyrosine kinase inhibitors in chronic myeloid leukemia
2011-000440-22Phase 4Active
- Sponsor
- Heidelberg University
- Start
- Feb 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib, nilotinib and dasatinib in chronic myelogenous leukemia (CML), sponsored by Heidelberg University. Primary endpoint: Molecular relapse-free survival after stopping TKI. Started Feb 2012; status: active.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2011-000440-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000440-22.